Tocagen Doses First Patient Intravenously in Clinical Trial of Selective Cancer Therapy, Toca 511 & Toca FC
The Toca 511 trial has been one of my favorites. It is a new type of gene therapy where a virus that only grows in tumor cells delivers a gene that can convert an oral nontoxic antifungal drug into a powerful chemotherapy, only in the cancer cells that were infected by the virus. There are now 3 separate clinical trials going on for the Tocagen treatment. The original 2 used local delivery of the virus to the area of the tumor. This one adds an IV injection of the virus and also local delivery. The idea is that it may be better able to hit those tumor cells that are spread out in the brain, far from where the MRI says the tumor is.
The Musella Foundation is one of the sponsors!
IF the story does not appear below, Click HERE to view the text of the story!
Note: The original website is displayed below - we have no control over it and are not responsible for the content of it, we just report it! IF you click on anything below, it will take you off of our website!
Original Source: http://www.tocagen.com/press/tocagen-doses-first-patient-intravenously-in-clinical-trial-of-selective-cancer-therapy-toca-511-toca-fc/
(Everything below this line is from VirtualTrials.com!)
Click HERE to return to brain tumor news headlines